GLYCAN THERAPEUTICS CORPORATION
Heparan sulfate hexasaccharide mimetic library with diverse, well-defined molecular structures synthesized through modular head-to-tail linkage of disaccharide building blocks
- Sector
- Biotech
- Headquarters
- Raleigh, NC
- Total capital
- $32.9M
- Federal grants
- $31M
- 39 awards · 2017–2025
- Rank in peer group#3 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $1.9M
- 2 awards · Health and Human S
- Rank in Biotech#138 of 4373
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of dekaparin to replace animal-sourced heparin$991K
- Federal grantHealth and Human S · Phase II · Development of anticoagulant sulfated glycans$1.1M
- Federal grantHealth and Human S · Phase II · Synthesis of the library of heparan sulfate hexasaccharide mimetics$1.1M
- Federal grantHealth and Human S · Phase II · Development of heparan sulfate-based therapeutics to treat inflammatory diseases$50K
- Federal grantHealth and Human S · Phase II · Development of anticoagulant sulfated glycans$1.1M
- Federal grantHealth and Human S · Phase II · Development of dekaparin to replace animal-sourced heparin$747K
- Federal grantHealth and Human S · Phase II · Synthesis of the library of heparan sulfate hexasaccharide mimetics$1.1M
Show 33 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of heparan sulfate-based therapeutics to treat inflammatory diseases$1.5M
- Federal grantHealth and Human S · Phase I · National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation$55K
- Federal grantHealth and Human S · Phase I · Synthesis of the library of heparan sulfate hexasaccharide mimetics$255K
- Federal grantHealth and Human S · Phase II · Development of heparan sulfate-based therapeutics to treat inflammatory diseases$874K
- Federal grantHealth and Human S · Phase I · Sulfated Carbohydrates for the Treatment of Periodontitis$348K
- Federal grantHealth and Human S · Phase II · Development of analytical methods for glycosaminoglycans from biological sources$989K
- Federal grantHealth and Human S · Phase I · Development of anticoagulant sulfated glycans$356K
- Federal grantHealth and Human S · Phase I · Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation$400K
- Federal grantHealth and Human S · Phase I · Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase$350K
- Federal grantHealth and Human S · Phase II · Development of analytical methods for glycosaminoglycans from biological sources$2M
- Federal grantHealth and Human S · Phase I · Construction of chondroitin sulfate microarray$332K
- Federal grantHealth and Human S · Phase I · Quantitative analysis of heparan sulfate using 13C-labeled standards$300K
- Federal grantHealth and Human S · Phase I · Development of heparan sulfate-based therapeutics to treat inflammatory diseases$231K
- Federal grantHealth and Human S · Phase II · Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$273K
- Federal grantHealth and Human S · Phase II · Developing Heparan Sulfate Glycan Array$968K
- Federal grantHealth and Human S · Phase II · Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$1.2M
- Federal grantHealth and Human S · Phase II · Development of a New Carbohydrate-based Anticoagulant Drug$1.2M
- Federal grantHealth and Human S · Phase II · Developing Heparan Sulfate Glycan Array$2.4M
- Federal grantHealth and Human S · Phase II · Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$2.7M
- Federal grantHealth and Human S · Phase II · LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides$120K
- Federal grantHealth and Human S · Phase II · Enzymatic synthesis of heparin sulfate and chondroitin sulfate$736K
- Federal grantHealth and Human S · Phase II · Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$537K
- Federal grantHealth and Human S · Phase II · Development of a New Carbohydrate-based Anticoagulant Drug$2.5M
- Federal grantHealth and Human S · Phase II · LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides$1.6M
- Federal grantHealth and Human S · Phase II · Enzymatic synthesis of heparin sulfate and chondroitin sulfate$744K
- Federal grantHealth and Human S · Phase II · Reactor for Insect Cell Culture$110K
- Federal grantHealth and Human S · Phase I · Developing Heparan Sulfate Glycan Array$147K
- Federal grantHealth and Human S · Phase II · Enzymatic synthesis of heparin sulfate and chondroitin sulfate$225K
- Federal grantHealth and Human S · Phase I · Developing Heparan Sulfate Glycan Array$297K
- Federal grantHealth and Human S · Phase I · Development of a New Carbohydrate based Anticoagulant Drug$225K
- Federal grantHealth and Human S · Phase I · Development of a New Carbohydrate-based Anticoagulant Drug$225K
- Federal contractHealth and Human S · Igf::ot::igf Chemoenzymatic Synthesis Of Heparin Sulfate$1.6M
- Federal contractHealth and Human S · Igf::ot::igf Chemoenzymatic Synthesis Of Heparin Sulfate Oligosaccarides$299K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#3 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- GENCIRQ, INC.Similar federal contract value in Biotech · $2M in contracts
- BUFFALO BIOLABS, LLCSimilar federal contract value in Biotech · $2M in contracts
- PEARL BIO, INC.Similar federal contract value in Biotech · $1.9M in contracts
- NAVIPOINT GENOMICS LLCSimilar federal contract value in Biotech · $1.9M in contracts
- IDBIOLOGICS INCSimilar federal contract value in Biotech · $1.9M in contracts
- PHOTOLITEC LLCSimilar federal contract value in Biotech · $1.9M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .